Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity-Reference-Cited by-同舟云学术

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Published:2014-03-20 Issue:12 Volume:123 Page:1957-1960
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kohrt Holbrook E.¹,Sagiv-Barfi Idit¹,Rafiq Sarwish²³,Herman Sarah E. M.³,Butchar Jonathon P.⁴,Cheney Carolyn³,Zhang Xiaoli⁵,Buggy Joseph J.⁶,Muthusamy Natarajan³,Levy Ronald¹,Johnson Amy J.²³⁷,Byrd John C.²³⁷

Affiliation:

1. Division of Oncology, Department of Medicine, Stanford University Cancer Institute, Stanford, CA

2. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

3. Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH

4. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The Ohio State University, Columbus, OH

5. Center for Biostatistics, The Ohio State University, Columbus, OH

6. Pharmacyclics, Inc., Sunnyvale, CA

7. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/12/1957/1375301/1957.pdf

Reference6 articles.

1. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

2. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.;Dubovsky;Blood,2013

3. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.;Khurana;J Immunol,2007

4. From the bench to the bedside: ways to improve rituximab efficacy.;Cartron;Blood,2004

5. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.;Kohrt;Blood,2011

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

2. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib;Hematological Oncology;2024-06-07

3. Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study;Annals of Intensive Care;2023-12-06

4. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies;Scientific Reports;2023-11-21

5. Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies;Frontiers in Cell and Developmental Biology;2023-10-31